1. Opening Hook
Just when markets were busy pricing Syngene as India’s cleanest CRDMO compounding story, Q3 FY26 arrived with a gentle reminder: science may be elegant, but numbers still pay the bills. Revenue slipped, margins took a beating, and PAT shrank faster than investor patience in a sideways market.
Yet, amid the financial sulk, Syngene calmly announced a Bristol Myers Squibb partnership extension till 2035, casually flexing its moat while the P&L gasped for breath. New biologics assets, AI-led workflows, shiny certifications, and sustainability trophies kept flowing—almost as if management was saying, “Relax, this is a transition quarter.”
But is it really just a timing issue, or are costs learning bad habits? Stick around—because the long-term story looks solid, but the short-term math is asking uncomfortable questions.
2. At a Glance
- Revenue down 3% YoY – Clients blinked, not vanished.
- EBITDA margin fell to 23% – From 30%, gravity finally won.
- PAT before exceptionals down 44% – Science worked, finance stumbled.
- Forex loss ₹233 mn – Dollar decided to become an enemy.
- BMS deal extended to 2035 – One client, infinite reassurance.
3. Management’s Key Commentary
“BMS has extended its long-standing partnership with Syngene through 2035.”
(Translation: One Big Pharma client trusts us more than quarterly margins 😏)
“We continue to invest in new technologies, AI, and novel modalities.”
(Translation: Costs
